Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

24/7 Wall St. aims to present some farther-looking insights based on Novo Nordisk’s own numbers ... the UK’s Association of British Pharmacy Industry over ethics violations tantamount to ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

an online weight loss company called Noom has begun selling smaller doses of compounded versions of Novo Nordisk's Wegovy GLP-1 drug. This development comes as the compounding pharmacy industry ...

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

Novo Nordisk A/S is replacing Chief Executive Officer ... for its Wegovy obesity shots that transformed the weight-loss industry and made the Danish company the star of corporate Europe.